Cargando…

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032185/ http://dx.doi.org/10.2147/CE.S67095

Ejemplares similares

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Family Wellbeing and Sexual Health of Patients Receiving Treatment for Prostate Cancer [Corrigendum]
Publicado: (2023)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
por: Masson, Susan, et al.
Publicado: (2016)

Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”
por: Al-Shamsi, Humaid O., et al.
Publicado: (2017)

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia [Corrigendum]
Publicado: (2013)

Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy [Corrigendum]
Publicado: (2022)

[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2023)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

A Prospective Study on the Efficacy of Cognitive Targeted Transrectal Ultrasound Prostate Biopsy in Diagnosing Clinically Significant Prostate Cancer [Corrigendum]
Publicado: (2021)

Corrigendum to “Natural Treatment Systems as Sustainable Ecotechnologies for the Developing Countries”
por: Mahmood, Qaisar, et al.
Publicado: (2018)

Corrigendum to “Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits” [Clin Oncol 27 (7) (2015) 420–426]
por: Ray, K.J., et al.
Publicado: (2016)

Corrigendum to ‘Roles of alternative RNA splicing of the Bif-1 gene by SRRM4 during the development of treatment-induced neuroendocrine prostate cancer’. [EBioMedicine 31 (2018) 267–275>
por: Gan, Yu, et al.
Publicado: (2020)

Corrigendum to “The Role of Antioxidants in Skin Cancer Prevention and Treatment”
por: Godić, Aleksandar, et al.
Publicado: (2020)

Corrigendum to “Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory” by Hiroki Watanabe
por: Watanabe, Hiroki
Publicado: (2016)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
por: Neubecker, Katherine, et al.
Publicado: (2017)

Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]
Publicado: (2019)

Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Publicado: (2023)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Publicado: (2018)

Corrigendum: Comparisons of Gastric Cancer Treatments: East vs. West
por: Bickenbach, Kai, et al.
Publicado: (2012)

[Corrigendum] miR‑195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression
por: Cai, Chao, et al.
Publicado: (2023)

On Carlsbad Treatment for Anglo-Indians: Corrigendum
Publicado: (1891)

Corrigendum: Acknowledgments. Effect of Photoselective Vaporization Prostatectomy on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia With or Without Intravesical Prostatic Protrusion
por: Kim, Myung Soo, et al.
Publicado: (2013)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Corrigendum: Correction of the Abstract. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study
por: Yaxley, William John, et al.
Publicado: (2022)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review [Corrigendum]
Publicado: (2023)

Corrigendum: treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Publicado: (2023)

Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]
por: Turco, Fabio, et al.
Publicado: (2022)

Corrigendum to: Development of bispecific antibodies in China: overview and prospects
por: Zhang, Jing, et al.
Publicado: (2022)

Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Publicado: (2020)

Corrigendum to ‘New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells’
por: Lee, Soo Ok, et al.
Publicado: (2020)

Corrigendum to “Clinical Trial Protocol: Developing an Image Classification Algorithm for Prostate Cancer Diagnosis on Three-dimensional Multiparametric Transrectal Ultrasound” [Eur. Urol. Open Sci. 49 (2023) 32–43]
por: Jager, Auke, et al.
Publicado: (2023)

Corrigendum to “Amiodarone Induced Hyponatremia Masquerading as Syndrome of Inappropriate Antidiuretic Hormone Secretion by Anaplastic Carcinoma of Prostate”
por: Dutta, Pinaki, et al.
Publicado: (2018)

Corrigendum to “Metabolic Syndrome, Inflammation, and Cancer”
por: Wu, Yong, et al.
Publicado: (2017)

Corrigendum to “Cell therapies in ovarian cancer”
Publicado: (2021)

Application of Radiosensitizers in Cancer Radiotherapy [Corrigendum]
Publicado: (2021)

The Blood Biomarkers of Thyroid Cancer [Corrigendum]
Publicado: (2022)

Corrigendum to: Imaging and cancer: a review
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hohi72ivqrpg42k2n7pkga7am1